Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 60

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Breast cancer stage III+2

Not recruiting

Study of Trastuzumab, Pertuzumab, and Chemotherapy Combination with Response-Guided Treatment for Patients with HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BOOG Study Center B.V.

Fallopian tube cancer+2

Not recruiting

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Malignant peritoneal neoplasm+2

Not recruiting

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:pharmaand GmbH

Ovarian cancer

Not recruiting

Study of Olaparib, Durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Polycystic ovarian syndrome

Not recruiting

Study on the Effects of Spironolactone, Pioglitazone, and Metformin for Adolescent Girls and Young Women with Polycystic Ovary Syndrome (PCOS)

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Metformin
  • Sponsor:Fundacio Sant Joan De Deu

Ovarian low malignant potential tumour

Not recruiting

Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Catequentinib Dihydrochloride
  • Sponsor:Advenchen Laboratories LLC

Prostate cancer

Not recruiting

Study of drug interactions between enzalutamide, morphine and edoxaban in patients with prostate cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Edoxaban
  • Sponsor:Stichting Radboud University Medical Center

Endometrial cancer stage I+1

Not recruiting

Study on Sentinel Lymph Node Mapping Using Gallium-68 Chloride and Tilmanocept in Patients with High-Risk Endometrial Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tilmanocept
  • Sponsor:Universitair Medisch Centrum Utrecht

Breast cancer

Not recruiting

Study of Trifluridine and Tipiracil in Patients with ER-Positive, HER2-Negative Advanced Breast Cancer After Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Trifluridine
  • Sponsor:BOOG Study Center B.V.

Endometriosis+1

Not recruiting

Study on the Effect of Triptorelin Before Frozen Embryo Transfer in Patients with Endometriosis or Adenomyosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Triptorelin
  • Sponsor:Hospital Foch

Malignant peritoneal neoplasm+2

Not recruiting

Study on the Effectiveness of Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Sodium Thiosulfate for Ovarian Cancer Patients Undergoing Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Centre Oscar Lambret

Malignant peritoneal neoplasm+2

Not recruiting

Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.